Received: 4 November 2019
Accepted: 25 February 2020
First Online: 24 March 2020
Ethics approval and consent to participate
: Present study does not fall within the remit of the Medical Research Involving Human Subjects Act (WMO). The study has been reviewed by the ethics committee on the basis of the Dutch Code of conduct for health research, the Dutch Code of conduct for responsible use, the Dutch Personal Data Protection Act and the Medical Treatment Agreement Act. The ethics committee has passed a positive judgment on the study.Patients received the questionnaires as standard care, the care as usual. No additional questionnaires were given for the aims of this study. No intervention was given.
: Not applicable.
: This study was not industry sponsored. KvdL, JC, SK, IK, MJ and CV report no disclosures. Prof. Jan Smeitink is the founding CEO of Khondrion BV.